These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 16917843)
1. Metabolism of dopamine by the nasal mucosa. Chemuturi NV; Donovan MD J Pharm Sci; 2006 Nov; 95(11):2507-15. PubMed ID: 16917843 [TBL] [Abstract][Full Text] [Related]
2. Role of dopamine transporter (DAT) in dopamine transport across the nasal mucosa. Chemuturi NV; Haraldsson JE; Prisinzano T; Donovan M Life Sci; 2006 Aug; 79(14):1391-8. PubMed ID: 16733058 [TBL] [Abstract][Full Text] [Related]
3. Role of organic cation transporters in dopamine uptake across olfactory and nasal respiratory tissues. Chemuturi NV; Donovan MD Mol Pharm; 2007; 4(6):936-42. PubMed ID: 17892261 [TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors. Pettersson F; Svensson P; Waters S; Waters N; Sonesson C J Med Chem; 2012 Apr; 55(7):3242-9. PubMed ID: 22385498 [TBL] [Abstract][Full Text] [Related]
8. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Iurlo M; Leone G; Schilström B; Linnér L; Nomikos G; Hertel P; Silvestrini B; Svensson H Psychopharmacology (Berl); 2001 Dec; 159(1):98-104. PubMed ID: 11797076 [TBL] [Abstract][Full Text] [Related]
9. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. Paterson IA; Juorio AV; Berry MD; Zhu MY J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846 [TBL] [Abstract][Full Text] [Related]
11. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Kandimalla KK; Donovan MD Pharm Res; 2005 Jul; 22(7):1121-8. PubMed ID: 16028013 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and metabolism of dopamine in the kidney. Effects of sodium chloride, monoamine oxidase inhibitors and alpha-human atrial natriuretic peptide. Soares-da-Silva P; Fernandes MH Am J Hypertens; 1990 Jun; 3(6 Pt 2):7S-10S. PubMed ID: 2143389 [TBL] [Abstract][Full Text] [Related]
13. Permeation and metabolism of cocaine in the nasal mucosa. Zhang H; Prisinzano TE; Donovan MD Eur J Drug Metab Pharmacokinet; 2012 Dec; 37(4):255-62. PubMed ID: 22351075 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain. Fuller RW; Robertson DW; Hemrick-Luecke SK J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775 [TBL] [Abstract][Full Text] [Related]
15. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine. Waldmeier PC; Maître L Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400 [No Abstract] [Full Text] [Related]
16. Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney. Fernandes MH; Soares-da-Silva P J Pharmacol Exp Ther; 1990 Dec; 255(3):1309-13. PubMed ID: 2124622 [TBL] [Abstract][Full Text] [Related]
17. Modification of dopamine release by selective inhibitors of MAO-B. Finberg JP; Lamensdorf I; Armoni T Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211 [TBL] [Abstract][Full Text] [Related]
18. Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells. Wei Q; Jurma OP; Andersen JK J Neurosci Res; 1997 Nov; 50(4):618-26. PubMed ID: 9404723 [TBL] [Abstract][Full Text] [Related]
19. In vivo effects of the monoamine oxidase inhibitors Ro 41-1049 and Ro 19-6327 on the production and fate of renal dopamine. Vieira-Coelho MA; Fernandes MH; Soares-da-Silva P J Neural Transm Suppl; 1994; 41():365-70. PubMed ID: 7931252 [TBL] [Abstract][Full Text] [Related]
20. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Youdim MB; Fridkin M; Zheng H Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]